Preclinical data support remyelinating potential of ABX-002
ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented by Autobahn’s academic collaborators at a pair of conferences this summer. “We are excited to […]